ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors
Published: Apr 01, 2021 CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the appointment of health innovation expert and executive Linda Maxwell, M.D., MBA, as an independent member of the company’s board of directors. The company also appointed CEO Richard Adcock to the board; he was named CEO of NantKwest in October and remains the CEO of the company after the merger of NantKwest with ImmunityBio in March. Both appointments are effective March 29, 2021. The nine-member ImmunityBio board is led by Fou...
Source: biospace.com